COVID‐19 outcomes in patients with autoimmune blistering disease

Open Access
Publisher Website
Google Scholar
Abstract
Autoimmune blistering diseases (AIBD) are often treated with immunosuppressive medications, including rituximab, yet the implications of these approaches during the COVID-19 pandemic are not fully understood. COVID-19 outcome studies in AIBD patients are limited by small sample sizes and interpretation complicated by advanced ages and comorbidities common in this population.
Funding Information
  • National Heart, Lung, and Blood Institute (T35HL007649)